Zhou Chengzhi

13 clinical trials · Sponsor

Record	Firm	Date
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC (NCT07685197)	Zhou Chengzhi	2026-07-01
Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP (NCT07599111)	Zhou Chengzhi	2026-04-01
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis (NCT07340892)	Zhou Chengzhi	2026-01-10
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC (NCT06597513)	Zhou Chengzhi	2024-12-01
Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine (NCT06670560)	Zhou Chengzhi	2024-09-05
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers (NCT06607770)	Zhou Chengzhi	2024-09-01
Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer (NCT06462105)	Zhou Chengzhi	2024-07-05
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy (NCT06607796)	Zhou Chengzhi	2024-03-01
Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP (NCT05280873)	Zhou Chengzhi	2021-10-10
Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC (NCT04858828)	Zhou Chengzhi	2021-06-01
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma (NCT04310943)	Zhou Chengzhi	2021-03-01
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC (NCT05001412)	Zhou Chengzhi	2021-01-27
Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma (NCT04312204)	Zhou Chengzhi	2020-03-01

Track Zhou Chengzhi automatically

Every clearance here is in the API, with alerts when new ones post.